

Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023

<https://marketpublishers.com/r/P1836025D56EN.html>

Date: June 2013

Pages: 217

Price: US\$ 2,635.00 (Single User License)

ID: P1836025D56EN

Abstracts

Contract manufacturing for pharma - discover top companies' revenue prospects

How are pharma contract manufacturing organisations (CMOs) performing? Visiongain's new report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions.

Our study analyses 30 leading CMOs. There you discover how revenues from drug production services can increase.

That way you find information you need on established and emerging companies. Read on to scan those organisations and see what their future market could be worth.

Forecasts and other data to help you stay ahead

In our new study you find analytical profiles of 30 top companies, and analyses of the overall industry. You discover historical data, market shares, revenue forecasts, and growth rates. See, too, qualitative analysis, business outlooks and developments.

There you also gain 141 tables, 58 charts, and five interviews with the industry.

Our work lets you assess the most lucrative services in outsourced drug making. That way you can stay ahead in knowledge of the CMO industry and market:

Finished dosage formulations (FDF) manufacturing

Active pharmaceutical ingredients (API) production.

See now how you can benefit your research, analyses and decisions, also saving time. The following sections highlight what you find in our new investigation.

Company profiles - activities, results, competition, and prospects

Our report analyses 30 leading companies. The content of each profile differs, depending on the company. In general, though, a profile gives you the following information:

Overview of the company's contract manufacturing services, including clients

Analysis of recent financial performance - overall revenue and that for CMO services

Assessment of developments - acquisitions, capacity expansions, new service offerings, and collaborations

SWOT analysis of the company - strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2013 to 2023

Forecasting of pharmaceutical contract manufacturing revenues to 2023, for 23 of the companies

Transcript of an interview by visiongain, for five of the companies.

Discover there what participants achieve, do, and say, helping you stay ahead.

European contract manufacturing organisations

First, our study gives you discussions, financial analyses, and commercial outlooks for 15 European CMOs, including these:

Lonza

Evonik Degussa

Royal DSM

Boehringer Ingelheim Biopharmaceuticals

Famar

Fareva

Vetter Pharma.

Discover what the future holds for those pharma service providers, including revenue outlooks to 2023.

Companies based in the US and Japan

Next, our report shows you developments and sales outlooks to 2023 for five other companies:

Catalent Pharma Solutions

Patheon

AbbVie Contract Manufacturing

Daito Pharmaceutical

Pfizer CentreSource.

Our work shows you where sales growth can occur. Many opportunities remain, with high, expanding revenues possible from 2013. You see where prospects exist.

Developed-market API specialists

You also discover outlooks for four top producers of active pharma ingredients:

Teva API

Esteve Qu?mica

Euticals

Cambrex.

Our report shows you potentials of the industry. You see possibilities for advancing technology and raising business performance.

India and China - analysis of pharma manufacturing service providers

Our work also assesses six Indian and Chinese companies. There you discover activities and prospects of these firms:

Dr. Reddy's Laboratories

Aurobindo Pharma

Divis Laboratories

Shandong Xinhua Pharmaceutical

Zhejiang Hisun Pharmaceutical

Zhejiang Huahai Pharmaceuticals.

That way you find sales data and underlying trends, seeing what the present and future hold.

Predictions for the worldwide pharma CMO market and submarkets

Our report also forecasts revenues to 2023 for the world contract manufacturing industry and its main segments: APIs and FDFs.

There you see overall world revenues in 2017 reaching \$66.4bn. Our analyses reveal high growth from 2013 to 2023. That work also predicts large companies and specialty healthcare firms will develop and prosper. She how and where, finding potential.

Biologics and biosimilars also hold promise. New biological therapies - including antibody-drug conjugates and regenerative medicines - interest CMOs and clients.

Discover opportunities and revenue predictions, then, for outsourced production of medicines. You investigate established and rising companies, finding their prospects.

Six ways Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023 helps you

In particular, our new investigation gives you the following knowledge:

Revenues to 2023 for the world CMO market and its components - discover that industry's prospects, finding promising places for investments and revenues

Profiles of 30 leading companies - assess services, strategies, sales results and outlooks, also gaining revenue forecasts to 2023 for 23 of the organisations

Interviews with 5 companies in the CMO industry - discover debates and opinions to help you stay ahead

Competition and opportunities - see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business

Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and gain advantages

Outlooks for established players and firms entering the sector - explore needs, practices, and outlooks for future success.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our new survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Prospects for pharma manufacturing providers - gain by ordering now

Our study lets you find data, trends, opportunities, and commercial predictions for outsourced drug and API production. Avoid missing out - please order our new report now.

Contents

COMPANIES LISTED

Abbott
AbbVie
AbbVie Contract Manufacturing
Abic (part of Teva)
Activa Capital
Aegerion Pharmaceuticals
Aenova
Aerofarm (part of Fareva)
Aesica Pharmaceuticals
Agence Nationale de s?curit? du M?dicament et des produits de sant? (ANSM) [France]
Ag??ncia Nacional de Vigil??ncia Sanit??ria (ANVISA) [Brazil]
Agennix
Ajinomoto OmniChem
AlgoNomics (part of Lonza)
Alliance Medical Products (part of Siegfried)
Almac Group
Alpharma
Amgen
Apexigen
Aptuit
Archimica (part of Euticals)
Arecor
Astellas Pharma
AstraZeneca
Athera Biotechnologies
Aurobindo Pharma
AuroSource (part of Aurobindo Pharma)
Avalanche Biotechnologies
Banner Pharmacaps (part of Patheon)
BaroFold
Barr-Pliva (part of Teva)
BASF
Bayer
BC Partners
Beijing Double-Crane Pharmaceutical (BDCP)

Bellwyck Packaging Solutions
Bend Research
Bentley Pharma (part of Teva)
Biogal
Bionomics
Blackstone Group
Boehringer Ingelheim
Boehringer Ingelheim Biopharmaceuticals
Bridgepoint
Bristol-Myers Squibb
Britest
Cambrex
Cardinal Health
Catalent (Shanghai) Clinical Trial Supplies Co
Catalent Pharma Solutions
Celladon
Celldex Therapeutics
CEVEC Pharmaceuticals
Chemo
Chemtrix
China National Pharmaceutical Group (Sinopharm)
Chirotech Technology (part of Dr. Reddy's Laboratories)
Cleveland BioLabs
Cobra Biologics Holding
CordenPharma (part of ICIG)
CPM ContractPharma (part of Aenova)
CTC Bio
Daiichi Sankyo
Daito Pharmaceutical
DeclImmune Therapeutics
Delmas Perfusion
Delpharm
DiFUSION Technologies
Divis Laboratories
Dr. Reddy's Laboratories
DSM Sinochem Pharmaceuticals
Durham University
Eclipse Therapeutics (part of Bionomics)
Eindhoven University of Technology

Eisai
Eli Lilly
EmulTech
Enobia Pharma (now Alexion Pharmaceuticals)
Enzon Pharmaceuticals
Esteve
Esteve Qu?mica (part of Esteve)
Euro Vital Pharma (part of Aenova)
European Medicines Agency (EMA)
Euticals
Evonik Degussa (part of Evonik Industries)
Evonik Industries
Excella (part of Fareva)
Excelvision (part of Fareva)
Exelixis
Famar
Fareva
Farma Lepori (part of Angelini Group)
Farmaclair (part of Fareva)
Farmaprojects
Farmea (part of Fareva)
Food and Drug Administration (FDA) [US]
Frazier Healthcare
Fuyang Xinghai Investment
Genentech (part of Roche)
G?n?rique M??me M?dicament (GEMME) [France]
Genzyme (part of Sanofi)
Gilead Sciences
GSK
Gyma Laboratories of America
Haupt Pharma
Health and Safety Executive (HSE) [UK]
Health Canada
Hisun-Pfizer Pharmaceuticals
Human Genome Sciences (part of GSK)
ICI (Imperial Chemical Industries)
Immune Pharmaceuticals
Indoco Remedies
Istituto de Angeli (part of Fareva)

Intellect Neurosciences
International Chemical Investors Group (ICIG)
Invita
Ipsen
Ivax API (part of Teva)
J&J
JK Pharmaceutical
Laboratoire Aguettant
Laboratoires Besins
Lanxess
Lonza
Marinopoulos Group
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Merck & Co.
Merck KGaA
Mesoblast
Molecular Partners
Mylan
National Institutes of Health (NIH) [US]
National Institutes of Health Center for Regenerative Medicine (NIH CRM) [US]
New Jersey Institute of Technology
Novartis
Novasep
OctoPlus (part of Dr. Reddy's Laboratories)
OmniChem (part of Ajinomoto OmniChem)
OncoMed Pharmaceuticals
Osiris Therapeutics
Otsuka Pharmaceutical
Pantec
Paranta Biosciences
Parexel
Patheon
Perrigo
PFC (now Teva PFC)
Pfizer
Pfizer CentreSource (part of Pfizer)
Pharmintraco
Piramal Pharma Solutions (part of Piramal Enterprises)
Plantex (part of Teva)

Poli Industria Chimica (part of Euticals)
Procaps
Prosintex Qu?mica
R5 Pharmaceuticals (part of Aesica Pharmaceuticals)
RAG
Ranbaxy Laboratories (part of Daiichi Sankyo)
Recepta Biopharma
Recipharm
Redwood Bioscience
Respirics (part of Zhejiang Hisun Pharmaceutical)
Roche
Royal DSM
Saltigo (part of Lanxess)
Sandoz (part of Novartis)
Sanofi
Sanwa Kagaku Kenkyusho Co
ScinoPharm
Seattle Genetics
Sentry BioPharma Services
Servier
Shandong Xinhua Pharmaceutical (Europe) (part of Shandong Xinhua Pharmaceutical)
Shandong Xinhua Pharmaceutical Co
Shanghai Pharmaceutical Co
ShangPharma
Shire
Sicor Biotech (part of Teva)
Siegfried
Sigmar Italia (part of Fareva)
Silverfleet Capital
Sinochem
SkyePharma
Softigel (part of Procaps)
State Food and Drug Administration (SFDA) [China]
SurModics (part of Evonik Industries)
Swedbank
SwissCo Services (part of Aenova)
Synkem
Takeda Pharmaceutical Company
Temmler Group (part of Aenova)

Temmler Ireland (part of Aenova)
Temmler Italia (part of Aenova)
Temmler Pharma (part of Aenova)
Temmler Werke (part of Aenova)
Tessengerlo Group
Teva API
Teva Pharmaceutical Industries
Th?ramax (part of Teva)
Thermo Fisher Scientific
Tianjin Tianyo Pharmaceuticals
Tianma Tianji
UCB
UMN Pharma
UniQure
University of Bradford
University of Leeds
Valdepharm (part of Fareva)
Vetter Pharma
ViroPharma
Vivante GMP Solutions (part of Lonza)
VTU Technology
Wanhui Beijing Double-Crane Pharmaceutical (part of BDCP)
West Pharmaceutical Services
Xinhua Pharmaceutical (Gaomi) Company (part of Shandong Xinhua Pharmaceutical)
XOMA
Yiwu Huayi Investment
Zenara Pharmaceuticals
Zhejiang Hisun Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Jiang Yuan Tang Biotechnology
Zibo Xinhua-Perrigo Pharmaceutical Company

About

Almac Group

Pharmaceutical companies are increasingly looking to cut the number of outsourced service providers that they use and therefore partnering with a company that can offer some clinical trial and manufacturing services will appeal. Almac is not reliant on a small number of clients for its revenue - the company serves more than 600 pharmaceutical partners in over 100 countries. However, there are weaknesses to Almac's service offering. For example, the company only offers commercial manufacturing of solid dosages, unlike many of its competitors, which also offer manufacturing for other formulations.

Investing in services for biopharmaceutical drug developers will act as a driver for growth for Almac during this decade. Increasing its refrigerated storage capacity and adding pegylation services will increase the number of biologics and biosimilars clients for Almac in the near future.

Pegylation of biological drugs is a common lifecycle management strategy for biological drug developers, particularly in the face of biosimilar competition, which is expected in the coming decade.

During the period 2013-2023, Almac's contract manufacturing revenue will grow strongly. Revenue grew much faster than the market as a whole between 2008 and 2011, visiongain notes. Growth will slow in the first half of the forecast period, with the company steadily utilising the increased capacity that it has added in recent years, through the addition of new clients. By 2017, Almac's revenue will have grown to \$0.68bn, up from an estimated \$0.48bn in 2012. Visiongain believes that in the first half of the period, growth an increased number of companies outsourcing development and manufacturing to Almac will drive growth.

I would like to order

Product name: Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023

Product link: <https://marketpublishers.com/r/P1836025D56EN.html>

Price: US\$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P1836025D56EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

